© 2019 IPHARMA

  • Facebook Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon

Possibilities of adaptive design implementation in clinical trial of next-in-class drugs

18.01.2017

 

IPHARMA article "Possibilities of adaptive design implementation in clinical trial of netx-in-class drugs" has been published in The Bulletin of the Scientific Center for Expert Evaluation of Medicinal Products has published (4, 2016).

 

The article investigates the possibility of streamlining the methodology of clinical studies of next-in-class drugs by implementing an adaptive design. The results of clinical trials are illustrated by three investigational products of diffrent pharmacological classes, including a DPP-4 inhibitor (Diabetes mellitus type 2), factor Xa inhibitor (VTE prevention in orthopedic surgery), and NNTRI (HIV). 

 

Authors:

IPHARMA LLC

Vostokova N.V., Executive Director, PharmD
Trakhtenberg J.A., Medical Director, MD, PhD


I. M. Sechenov First Moscow State Medical University
Smolyarchuk E.A., Associate professor of the Department of Clinical Pharmacology and Internal Medicine Propaedeutics, PhD
Svistunov A.A., First Vice-Rector—Vice-Rector for Innovation Policy and International Activities, MD, professor

 

The article "Possibilities of adaptive design implementation in clinical trial of netx-in-class drugs"

 

 

Please reload

Недавние посты
Please reload

Архив
Please reload